Gap Debate: 20260403-222543

0.795

APOE4

Engineering cell-type specific lipid nanoparticles that selectively target astrocytic APOE4 expression while preserving microglial APOE function. This approach leverages the finding that astrocytic AP

0.745

IL1A, TNF, C1Q

Selective modulation of astrocyte-derived inflammatory signals that aberrantly activate microglia, using engineered biologics that specifically block pathological astrocyte-microglia crosstalk while p

0.695

DAP12, SYK, PLCG2

Pharmacological activation of TREM2-independent microglial protective pathways identified through single-cell transcriptomics. This bypasses the requirement for functional TREM2 while still activating

0.640

CST, GAL3ST1

Direct delivery of synthetic myelin sulfatides or precursors specifically to oligodendrocytes using oligodendrocyte-selective targeting peptides. This targets the recently discovered mechanism where o

0.532

PDK1, PFKFB3, LDHA

Targeted metabolic reprogramming of oligodendrocyte progenitor cells (OPCs) to enhance their differentiation and myelination capacity through cell-type specific delivery of metabolic modulators that a

0.510

WNT3A, CTNNB1, TCF7L2

Targeted reactivation of WNT signaling specifically in inhibitory interneurons using neuron subtype-specific viral vectors. This addresses the discovered selective vulnerability of inhibitory neurons

0.473

SNCA

Cell-type specific normalization of α-synuclein expression using engineered transcriptional modulators that account for the neuronal cell type-dependent regulation of SNCA expression, targeting only v